David Badesch, MD

Professional Titles

• Clinical Director, Pulmonary Hypertension Center
• Chair, Pharmacy and Therapeutics Committee

Publications

• Ann Intern Medicine 143:282-292;2005
• Thorax. 2005 Dec;60(12):1025-30
• J Am Coll Card (JACC) 46(3)529-35;2005
• Rheum Dis Clin North Am. 2005 Aug;31(3):451-64, vi
• New Engl J Med 353:2148-2157;2005
• Eur Respir J 2005; 26:1110-1118
• Rheumatic Disease Clinics of North America”, Ed. Grossman JM and Furst DE. Saunders, Philadelphia, PA, 2005
• Textbook of Critical Care Medicine”, Fink M, Abraham E, Vincent J-L, Kochanek P., Elsevier Saunders (Philadelphia, Pennsylvania), 2005
• Robyn J. Barst, MD, David Langleben, MD, David Badesch, MD, Adaani Frost, MD, E. Clinton Lawrence, MD, Shelley Shapiro, MD, Robert Naeije, MD, Nazzareno Galie, MD, on behalf of the STRIDE-2 Study Group. Treatment of PulmonaryArterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
• Quaife RA, Chen MY, Lynch D, Badesch DB, Groves BM, Wolfel E, Robertson AD, Bristow MR, Voelkel NF. Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress. Eur J Med Res 2006; 11:214-20.
• McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
• Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: An American experience. Am Heart J 2006;152:521-6.
• Hemstreet BA, Stolpman N, BadeschDB, May SK, McCollum M. Potassium and phosphorus repletion in hospitalized patients: implications for clinical practice and the potential use of healthcare information technology to improve prescribing and patient safety. Current Medical Research and Opinions 2006;22:2449-2455.
• Fagan, KA, Badesch DB, Elliott CG, Frantz RP. Recapping Highlights from the 2006 PHA Scientific Sessions: Reviewing New Perspectives on Inflammation, Genetics, and Imaging; Redefining Exercise-Induced PH; Future Considerations in Translational Research. Advances in Pulmonary Hypertension 2006; 5:34-39.
• Beutz M, Bull T, Badesch DB. Oral Therapies for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension
• 76. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy guidelines for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. CHEST 2007;131:1917-1928
• 77. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G; SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec;34(12):2417-22.
• 91. Adaani E. Frost, David B. Badesch, Robyn J. Barst, Raymond L. Benza, C. Gregory Elliott, Harrison Farber, Abby Krichman, Theodore G. Liou, Gary E. Raskob, Scott Giles, Kathleen Feldkircher, Michelle Turner, and Michael D. McGoon. A Comparison of REVEAL registry data with other/prior registries of pulmonary arterial hypertension (PAH). Chest Meeting Abstracts 2008 134: p134001.
• 92. Omar A. Minai, Steven D. Nathan, Nicholas S. Hill, David B. Badesch, and James K. Stoller. Practice patterns regarding managing pulmonary hypertension in patients with parenchymal lung diseases: results of an ACCP survey. Chest Meeting Abstracts 2008 134: p134002.
• 93. Lewis J. Rubin, David Badesch, Thomas Fleming, Nazzareno Gali, Gerald Simonneau, Hossein A. Ghofrani, Nizamul Islam, Vallerie V. McLaughlin, and Robyn J. Barst. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. Chest Meeting Abstracts 2008 134: s40003.
• 94. Harrison W. Farber, Michael D. McGoon, Raymond L. Benza, Prieya Wason, Dave P. Miller, David B. Badesch. REVEAL Registry: Implications of Functional Class and Hemodynamics on Outcome in Patients with PAH. Accepted for oral presentation at the ISHLT 29th Annual Meeting and Scientific Sessions, April 22-25, 2009, in Paris, France.
• 95. Robyn Barst, Dunbar Ivy, David B. Badesch, Raymond L. Benza, C. Gregory Elliott, Harrison W. Farber, Adaani E. Frost, Abby Krichman, Theodore G. Liou, Gary E. Raskob, Michael D. McGoon. REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension. Accepted for presentation at the ISHLT 29th Annual Meeting and Scientific Sessions, April 22-25, 2009, in Paris, France.
• 96. Robyn Barst, Dunbar Ivy, David B. Badesch, Raymond L. Benza, C. Gregory Elliott, Harrison W. Farber, Adaani E. Frost, Abby Krichman, Theodore G. Liou, Gary E. Raskob, Michael D. McGoon. REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated With Congenital Heart Disease. Accepted for presentation at the ISHLT 29th Annual Meeting and Scientific Sessions, April 22-25, 2009, in Paris, France.
• Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined end points in pulmonary arterial hypertension. Proceedings of the American Thoracic Society 2008;5:617-622.
• 80. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment in pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117(23); 3010-9.
• 81. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R; Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. CHEST 2008; 134(4); 775-82.
• 82. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ; Ambrisentan Therapy in Patients with Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. CHEST 2008.
• 83. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21;149(8):521-30.
• McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619.
• McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28;119(16):2250-94.
• Bansal S, Badesch D, Bull T, Schrier RW. Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. Contemp Clin Trials. 2009 Apr 16.
• Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB, Brown RS Jr, Taichman DB, Trotter J, Zacks S, Horn EM, Kawut SM. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Pulmonary Vascular Complications of Liver Disease Study Group. Chest. 2009 Jun;135(6):1470-5.
• McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End Points and Clinical Trial Design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107.
• Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-66.
• Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9;119(22):2894-903.
• Jing ZC, Xu XQ, Badesch DB, Jiang X, Wu Y, Liu JM, Wang Y, Pan L, Li HP, Pu JL, Zhang ZL, Yang YJ. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009 Aug;103(8):1136-42. Epub 2009 Apr 28.
• Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD.Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. Journal of Rheumatology (0315-162X), 36 (10), p. 2244.
• Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon M. Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry. Chest; Prepublished online October 16, 2009; DOI 10.1378/chest.09-1140.
• Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ; ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17;54(21):1971-81.
• 97. Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., Liou, T. G., McGoon, M. D. (in press). Predicting Survival in Pulmonary Arterial Hypertension: Insights from the REVEAL Registry. Circulation. 2010 Jul 13;122(2):164-72. Epub 2010 Jun 28.
• 96. McCollister D, Beutz M, McLaughlin V, Rumsfeld J, Masoudi F, Tripputi M, Yaeger T, Weintraub P, Badesch D. Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status. Psychosomatics. 2010; 51:339-339.e.
• 98. Chung, L., Liu, J., Parsons, L., Hassoun, P. M., McGoon, M. D., Badesch, D. B., Miller, D. P., Nicolls, M. R., & Zamanian, R. T. (in press). Characterization of Connective Tissue Disease Associated Pulmonary Arterial Hypertension from the REVEAL Registry: Identifying Systemic Sclerosis as a Unique Phenotype. Chest. 2010 May 27. [Epub ahead of print]
• 99. Minai OA, Nathan SD, Hill NS, Badesch DB, Stoller JK. Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. Respir Med. 2010 May;104(5):741-8. Epub 2010 Jan 21.
• 100. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May;16 Suppl 1:S11-9. Review.
• 101. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The Changing Picture of Pulmonary Arterial Hypertension (PAH) Patients in the United States: How the REVEAL Registry Differs From Historic and Non-US Contemporary Registries. Chest. 2010 Jun 17. [Epub ahead of print] Chest 2011;139;128-137.
• Rubin, Lewis; Badesch, David; Fleming, Thomas; Galie, Nazzareno; Simonneau, Gerald; Ghofrani, Ardeschir; Oakes, Michael; Layton, Gary; Serdarevic-Pehar, Marjana; McLaughlin, V.; Barst, Robyn. Long-Term Treatment with Sildenafil Citrate in Pulmonary Arterial Hypertension: SUPER-2. CHEST, in press.
• An Evaluation of Long-Term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From REVEAL. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. Chest. 2012 Jan 26. [Epub ahead of print]
• Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR; Walk-PHASST Investigators. Circulation. 2011 Sep 27;124(13):1452-60. Epub 2011 Sep 6.
• ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ; for the ARIES-3 Study Group. Cardiovasc Ther. 2011 Jun 20. doi: 10.1111/j.1755-5922.2011.00279.x. [Epub ahead of print]
• Portopulmonary Hypertension: A Report From the US-Based REVEAL Registry. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Chest. 2011 Jul 21. [Epub ahead of print]
• The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. Chest. 2012 Feb;141(2):354-62. Epub 2011 Jun 16.
• Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group. Chest. 2011 Nov;140(5):1274-83. Epub 2011 May 5.
• Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients. Blood. 2011 Jul 28;118(4):855-64. Epub 2011 Apr 28.
• Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Mayo Clin Proc. 2011 Feb;86(2):105-12.
• Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. J Heart Lung Transplant. 2011 Jun;30(6):632-43. Epub 2011 Jan 21.
• The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. Chest. 2011 Jan;139(1):128-37. Epub 2010 Jun 17. Erratum in: Chest. 2011 Oct;140(4):1106.
• 106. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012 Feb;141(2):354-62. Epub 2011 Jun 16. PMID: 21680644 [PubMed - indexed for MEDLINE].
• 107. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Portopulmonary Hypertension: A Report From the US-Based REVEAL Registry. Chest. 2012 Apr;141(4):906-15. Epub 2011 Jul 21. PMID: 21778257 [PubMed - in process].
• 108. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ; for the ARIES-3 Study Group. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovasc Ther. 2012 Apr;30(2):93-99. doi: 10.1111/j.1755-5922.2011.00279.x. Epub 2011 Jun 20.
• 110. McCollister D, Weintraub P, Badesch DB. Depression: Beyond description as an important comorbidity in PAH – The next steps? Advances in Pulmonary Hypertension, Winter 2012, 10 (4).
• 111. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest. 2012 Jan 26. [Epub ahead of print] PMID: 22281797 [PubMed - as supplied by publisher].
• 112. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012 Dec;142(6):1383-90. doi: 10.1378/chest.11-2212. PMID: 22628490 [PubMed - in process].
• 113. Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 1;21(125):234-8. doi: 10.1183/09059180.00003712. Review. PMID: 22941888 [PubMed - indexed for MEDLINE].
• 114. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst R, Machado R, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris C, Rosenzweig EB, Badesch DB, Lanzkron S, Castro O, Goldsmith JC, Gordeuk V, Gladwin MT. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2012 Sep 14. [Epub ahead of print] PMID: 22983573 [PubMed - as supplied by publisher.
• The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT; Walk-PHASST Investigators and Patients. Haematologica. 2013 Mar;98(3):464-72. doi: 10.3324/haematol.2012.068965. Epub 2012 Sep 14. PMID: 22983573 [PubMed - indexed for MEDLINE]
• Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Chest. 2013 Nov;144(5):1521-9. doi: 10.1378/chest.12-3023. PMID: 23907471 [PubMed - indexed for MEDLINE]
• Definitions and diagnosis of pulmonary hypertension. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. PMID: 24355641 [PubMed - in process]
• Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16. PMID: 24439983 [PubMed - in process]
• Simonneau, Rubin, Galie, Fleming, Engel, Kramer, Serdarevic-Pehar, Layton, Sitbon, Badesch, Min, Bruce, CecileLong-Term Sildenafil Added to Intravenous Epoprostenol in Patients With Pulmonary Arterial Hypertension Journal of Heart and Lung Transplantation. In Press.
• Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2014 Sep 28. [Epub ahead of print] PubMed PMID: 25447572
• Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW. Hospitalization and Survival in Patients Utilizing Epoprostenol for Injection in the PROSPECT Observational Study. Chest. 2014 Oct 9. [Epub ahead of print] PubMed PMID: 25320967
• Hunt JM, Risbano MG, Messenger JC, Carroll J, Badesch D, Lowes BD, Casserly IP, Kay J, Bull TM. Timed response to inhaled nitric oxide in pulmonary hypertension. Pulm Circ. 2014 Mar;4(1):103-9. PubMed PMID: 25006425
• Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF, walk-PHaSST Investigators and Patients. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014;9(7):e99489. PubMed PMID: 24988120
• Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug;146(2):449-75. PubMed PMID: 24937180
• Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB, PACES Study Group. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Jul;33(7):689-97. PubMed PMID: 24815795
• Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT, American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. PubMed PMID: 24628312
• Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb;167(2):218-225.e1. PubMed PMID: 24439983
• Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. Chest. 2017 Jan;151(1):90-105. PubMed PMID: 27615023
• McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, Wiklund I, Peacock A. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016 Jun 14;17(1):72. PubMed PMID: 27301413
• Robinson JC, Pugliese SC, Fox DL, Badesch DB. Anticoagulation in Pulmonary Arterial Hypertension. Curr Hypertens Rep. 2016 Jun;18(6):47. PubMed PMID: 27137522
• Naeije R, Saggar R, Badesch D, Rajagopalan S, Gargani L, Rischard F, Ferrara F, Marra AM, D'Alto M, Bull TM, Saggar R, Grünig E, Bossone E. Exercise-Induced Pulmonary Hypertension Translating Pathophysiological Concepts into Clinical Practice. Chest. 2018 Jan 27. [Epub ahead of print] PubMed PMID: 29382472
• Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 Jan 16. [Epub ahead of print] PubMed PMID: 29355551
• McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin. 2018 Feb;34(2):263-273. PubMed PMID: 29132217
• Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. Chest. 2017 Jan;151(1):90-105. PubMed PMID: 27615023
• Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A. Diagnosis of pulmonary hypertension. Eur Respir J. 2018 Dec 13. [Epub ahead of print] PubMed PMID: 30545972
• Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, Ross RVM, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Noordegraaf AV, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2018 Dec 5. [Epub ahead of print] PubMed PMID: 30527956
• Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2018 Oct 14. [Epub ahead of print] PubMed PMID: 30415942
• Frantz RP, Zhao C, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Mink DR, Selej M, Benza RL. Response. Chest. 2018 Nov;154(5):1262-1264. PubMed PMID: 30409362
• Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018 Oct;154(4):848-861. PubMed PMID: 29705220
• Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 Aug;37(8):948-955. PubMed PMID: 29653800
• Parikh KS, Gray MP, Rubin LJ, Badesch D, Krasuski RA. Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulm Circ. 2018 Jan-Mar;8(1):2045893217743184. PubMed PMID: 29534640
• Naeije R, Saggar R, Badesch D, Rajagopalan S, Gargani L, Rischard F, Ferrara F, Marra AM, D' Alto M, Bull TM, Saggar R, Grünig E, Bossone E. Exercise-Induced Pulmonary Hypertension: Translating Pathophysiological Concepts Into Clinical Practice. Chest. 2018 Jul;154(1):10-15. PubMed PMID: 29382472
• Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 Jul;154(1):126-135. PubMed PMID: 29355551
• McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin. 2018 Feb;34(2):263-273. PubMed PMID: 29132217
• Klinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Response. Chest. 2019 Jul;156(1):187-188. PubMed PMID: 31279370
• Elliott CG, Austin ED, Badesch D, Badlam J, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC. United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulm Circ. 2019 Apr-Jun;9(2):2045894019851696. PubMed PMID: 31099303
• Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019 Mar;155(3):565-586. PubMed PMID: 30660783
• Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). PubMed PMID: 30545972
• Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 Mar;7(3):227-238. PubMed PMID: 30527956
• Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2019 Jun;48(6):1059-1067. PubMed PMID: 30415942
• Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary P, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a Measure of Health-Related Quality of Life in Pulmonary Arterial Hypertension: data from PHAR. Eur Respir J. 2020 Nov 26. [Epub ahead of print] PubMed PMID: 33243844
• Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, Shlobin O, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulm Circ. 2020 Oct-Dec;10(4):2045894020964342. PubMed PMID: 33240488
• Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N. Prediction of Health-Related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR). Am J Respir Crit Care Med. 2020 Nov 19. [Epub ahead of print] PubMed PMID: 33211974
• Min J, Feng R, Badesch D, Berman-Rosenzweig E, Burger C, Chakinala M, De Marco T, Feldman J, Hemnes A, Horn EM, Lammi M, Mathai S, McConnell JW, Presberg K, Robinson J, Sager J, Shlobin OA, Simon M, Thenappan T, Ventetuolo C, Al-Naamani N. Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). Ann Am Thorac Soc. 2020 Oct 21. [Epub ahead of print] PubMed PMID: 33085915
• Kolaitis NA, Zamanian RT, de Jesus Perez VA, Badesch DB, Benza RL, Burger CD, Chakinala MM, Elwing JM, Feldman J, Lammi MR, Mathai SC, McConnell JW, Presberg KW, Robinson JC, Sager J, Shlobin OA, Simon MA, Kawut SM, Glidden DV, Singer JP, De Marco T. Clinical Differences and Outcomes between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension in the PHAR. Ann Am Thorac Soc. 2020 Oct 16. [Epub ahead of print] PubMed PMID: 33064950
• Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021 Jan;159(1):311-327. PubMed PMID: 32858008
• D'Alto M, Badesch D, Bossone E, Borlaug BA, Brittain E, Humbert M, Naeije R. A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest. 2020 Aug 14. [Epub ahead of print] PubMed PMID: 32805242
• Frantz RP, Chin KM, Zhao C, Flynn M, Badesch D. Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. Pulm Circ. 2020 Apr-Jun;10(2):2045894020923957. PubMed PMID: 32489644
• Badlam JB, Badesch D, Brittain E, Cordell S, Ding T, Fox K, Hemnes A, Loyd J, Pugh M, Robbins I, Yu C, Austin ED. Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case-control study. Pulm Circ. 2020 Jan-Mar;10(1):2045894020908786. PubMed PMID: 32166018
• Lee MH, Doran J, Bang TJ, Hohsfield R, Hountras P, Boddie G, Wagh MS, Badesch D, Bull TM. Pulmonary Arterial Hypertension and Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Novel Association?. Chest. 2021 Dec;160(6):2260-2265. PubMed PMID: 34284002
• DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulm Circ. 2021 Jul-Sep;11(3):20458940211020913. PubMed PMID: 34158918
• Forbes LM, Gu S, Badesch DB. Surrogate Markers for Pulmonary Hypertension May Inform Prognosis in Lung Cancer. Am J Respir Crit Care Med. 2021 May 15;203(10):1220-1221. PubMed PMID: 33789070
• Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. PubMed PMID: 33789009
• Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2021 Jul 15;204(2):209-221. PubMed PMID: 33651671
• Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 Feb;57(2). PubMed PMID: 33243844
• Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N. Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med. 2021 Mar 15;203(6):761-764. PubMed PMID: 33211974
• Kolaitis NA, Zamanian RT, de Jesus Perez VA, Badesch DB, Benza RL, Burger CD, Chakinala MM, Elwing JM, Feldman J, Lammi MR, Mathai SC, McConnell JW, Presberg KW, Robinson JC, Sager J, Shlobin OA, Simon MA, Kawut SM, Glidden DV, Singer JP, De Marco T. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc. 2021 Apr;18(4):613-622. PubMed PMID: 33064950
• Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021 Jan;159(1):311-327. PubMed PMID: 32858008
• D'Alto M, Badesch D, Bossone E, Borlaug BA, Brittain E, Humbert M, Naeije R. A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest. 2021 Feb;159(2):791-797. PubMed PMID: 32805242
• DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry. Pulm Circ. 2022 Oct;12(4):e12172. PubMed PMID: 36540874
• Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 Jan;61(1). PubMed PMID: 36041750
• Hill NS, Feldman JP, Sahay S, Benza RL, Preston IR, Badesch D, Frantz RP, Patel S, Galloway A, Bull TM. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022 Jul;12(3):e12119. PubMed PMID: 36034402
• Grinnan D, Kang L, DeWilde C, Badesch D, Benza R, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Klinger J, McConnell J, Rosenzweig EB, Sager J, Shlobin O, Zamanian R. Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation. Pulm Circ. 2022 Jul;12(3):e12120. PubMed PMID: 35911181
• Minhas J, Narasimmal SP, Bull TM, De Marco T, Mc Connell JW, Lammi MR, Thenappan T, Feldman JP, Sager JS, Badesch DB, Ryan JJ, Grinnan DC, Zwicke D, Horn EM, Elwing JM, Moss JE, Eggert M, Shlobin OA, Frantz RP, Bartolome SD, Mathai SC, Mazimba S, Pugliese SC, Al-Naamani N. Corrigendum for health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry. Pulm Circ. 2022 Apr;12(2):e12085. PubMed PMID: 35783032
• Bolt MA, MaWhinney S, Pattee JW, Erlandson KM, Badesch DB, Peterson RA. Inference following multiple imputation for generalized additive models: an investigation of the median p-value rule with applications to the Pulmonary Hypertension Association Registry and Colorado COVID-19 hospitalization data. BMC Med Res Methodol. 2022 May 21;22(1):148. PubMed PMID: 35597908
• Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022 May 3;11(9):e024969. PubMed PMID: 35475351
• Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Waxman AB, Grünig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Lin J, Johnson-Levonas AO, de Oliveira Pena J, Humbert M, Hoeper MM. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. 2023 Sep;62(3). PubMed PMID: 37696565
• Gomberg-Maitland M, McLaughlin VV, Badesch DB, Ghofrani HA, Hoeper MM, Humbert M, Preston IR, Souza R, Waxman AB, de Oliveira Pena J, Lu JT, Manimaran S, Gibbs JSR. Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR Study. JACC Heart Fail. 2023 Oct;11(10):1457-1459. PubMed PMID: 37452806
• Mayer M, Badesch DB, Nielsen KH, Kawut S, Bull T, Ryan JJ, Sager J, Mazimba S, Hemnes A, Klinger J, Runo J, McConnell JW, De Marco T, Chakinala MM, Yung D, Elwing J, Kaplan A, Argula R, Pomponio R, Peterson R, Hountras P. Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry. Pulm Circ. 2023 Apr;13(2):e12233. PubMed PMID: 37159803
• Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. PubMed PMID: 36877098
• McCormick A, Krishnan A, Badesch D, Benza RL, Bull TM, De Marco T, Feldman J, Hemnes AR, Hirsch R, Horn E, Kennedy J, Mathai SC, McConnell W, Pugliese SC, Sager JS, Shlobin OA, Simon MA, Lammi MR. Pulmonary artery compliance in different forms of pulmonary hypertension. Heart. 2023 Jun 26;109(14):1098-1105. PubMed PMID: 36787969
• Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 Jan;61(1). PubMed PMID: 36041750

Professional Memberships

• American College of Chest Physicians, Fellow
• American Thoracic Society (ATS), Member
• American College of Physicians (ACP), Fellow
• Society of Critical Care Medicine, Member

Practice Locations

• University of Colorado Hospital

Specialty Information

• Pulmonary Disease, Board Certification (1988)
• Internal Medicine, Board Certification (1986)
• Pulmonary Disease and Critical Care Medicine, Board Certification (2009)

• Lungs and Breathing - Pulmonary Hypertension
• Lungs and Breathing